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Abstract: Background: While immunotherapy moved to the forefront of treatment of various cancers,
it remains underexplored for uterine cancer. This might be due to the small patient population
with advanced endometrial carcinoma and uterine sarcoma. Data about immunotherapeutic targets
are scarce in endometrial carcinoma and lacking in uterine sarcoma. Methods: Expression of five
tumor-associated antigens (TAA) (BORIS, MUC1, hTERT, MAGE-A3 and Sp17) was validated in
uterine tumor samples by immunohistochemistry (IHC) and/or quantitative reverse-transcriptase
polymerase chain reaction (qRT-PCR). TAA immunogenicity was analyzed by determining
spontaneous T cell responses towards overlapping peptide pools covering the whole TAA in patient
blood. Results: At mRNA level, MAGE-A3 and Sp17 were overexpressed in a minority of patients and
BORIS was moderately overexpressed (26% in endometrial carcinoma and 62% in uterine sarcoma).
hTERT was overexpressed in the vast majority of tumors. On protein level, MUC1 was upregulated
in primary, recurrent and metastatic EMCAR and in metastatic US tumors. hTERT protein was
highly expressed in both normal and malignant tissue. Spontaneous TAA-specific T cell responses
were detected in a minority of patients, except for hTERT to which T cell responses occurred more
frequently. Conclusions: These data point to MUC1 and hTERT as most suitable targets based on
expression levels and T cell immunogenicity for use in immunotherapeutic regimens.
Keywords: tumor-associated antigens; expression; immunogenicity; endometrial carcinoma;
uterine sarcoma
1. Introduction
Cancer immunotherapy, based on the recognition of the so-called tumor-associated antigens
(TAA), is a valid therapeutic option for many types of cancer. Numerous different TAA have already
been described to date. In 2009, Cheever et al. ranked a list of known TAA according to a whole
array of characteristics, such as tissue expression, presentation in major histocompatibility complex
(MHC) context, and immunogenicity [1]. Several TAA have already been described in various tumor
types and tested in (pre)clinical immunotherapeutic settings with varying success [2]. Most data have
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been gathered in among others melanoma [3–6], glioblastoma [7,8], renal cell carcinoma (RCC) [9],
prostate cancer [8] and hematological malignancies [10].
Tumor immunology and immunotherapy are, however, largely underexplored in uterine cancer.
Although some of these known antigens have already been described in uterine cancer, only few
studies were done to verify their potential use in immunotherapeutic strategies. Uterine tumors
have been shown to be immunogenic, which is exemplified by the presence of tumor-infiltrating
lymphocytes and macrophages [11,12]. Some immunotherapy studies have already been performed
in uterine tumors using WT1 as target antigen [5,13,14]. Other (pre)clinical studies in uterine tumors
based on the targeting of antigens have mainly focused on the use of whole tumor lysate [15,16].
The current research is focused on the validation of some of the described TAA in uterine tumors.
Specifically, we have analyzed the following antigens: brother of the regulator of imprinted sites
(BORIS), mucin-1 (MUC1), human telomerase reverse transcriptase (hTERT), sperm protein 17 (Sp17)
and melanoma-associated antigen A3 (MAGE-A3). BORIS, Sp17 and MAGE-A3 are members of
the cancer-testis antigen family. In normal tissues, their expression is restricted to male germ cells,
fetal ovary, placenta and immature gametes [17], while they are expressed in several types of cancer,
among which breast cancer [18,19], making them attractive targets for immunotherapeutic purposes.
hTERT is considered as a universal TAA. This antigen plays an essential role in the survival of
tumor cells, which makes it particularly attractive. It is absent in adult tissues, with the exception of
proliferating tissues, while being up-regulated in dividing tumor cells, which fortifies its suitability
as target TAA [20,21]. MUC1 is an epithelial antigen, constitutively expressed on normal epithelium
in its wild-type form. The TAA MUC1, however, discriminates itself from the wild-type form by
a hypoglycosylation pattern, exposing new epitopes, which can attract antigen-specific T cells [22].
These antigens were arbitrarily selected based on an analysis of the available data of these antigens
concerning: (a) their presence in uterine tumors; (b) their ranking in the prioritization list described
above; (c) available data on their application in immunotherapeutic regimens in other tumor types;
and (d) their specific expression/function in tumorigenesis.
Besides these shared TAA, recently, patient-specific mutations have attracted attention as
tumor-specific neoantigens that are recognized by specific T cells and to which no immune tolerance is
present [23–25]. Hence, these neoantigens most probably constitute the ideal targets of immunotherapy.
The presence of neoantigens has been described in endometrial cancer, predominantly in polymerase E
(POLE)-mutated and microsatellite instable (MSI) tumors, which is consistent with the high mutation
burden in these tumors [26]. However, the identification of neoantigens is a cumbersome and
time-consuming process, which makes it difficult to implement in immunotherapeutic approaches.
To our knowledge, neoantigens have not been described in uterine sarcoma, which could be explained
by the fact that these tumors contain less point mutations but contain rather complex chromosomal
rearrangements. One type of these rearrangements, however, chromosomal translocations, can give
rise to the formation of unique new fusion proteins, which could be recognized by the immune
system [27–29]. However, this phenomenon has not been described yet in translocation containing
uterine sarcomas [30].
We currently aim to validate the presence of the above-described shared TAA in endometrial
carcinomas and evaluate their expression in uterine sarcoma, which has, to our knowledge, not been
described before. In addition, we evaluate their immunogenicity by analyzing the naturally-occurring
in vivo TAA-specific T cell responses. The combined data will give a view on the applicability of the
currently investigated shared TAA for immunotherapy in uterine cancer patients.
2. Results
2.1. TAA Expression in Normal Human Tissues and Tumor Cell Lines at mRNA Level
Prior to testing primary patient material, mRNA expression levels of the different TAA were
assessed on a panel of normal human tissues. Of the currently selected antigens, PCR analysis was
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performed for all antigens, except for MUC1. The difference between the wild-type and tumor antigen
MUC1 is a difference in glycosylation pattern. This is a post-translational modification and thus cannot
be detected at the level of RNA. As expected, the cancer-testis antigens BORIS, MAGE-A3 and Sp17
were expressed at highest levels in testis, but for BORIS and Sp17 a fairly high level of background
expression could also be observed in other tissues. MAGE-A3 expression was more restricted to
testis (Table S1). With regard to the universal TAA hTERT, the highest expression levels were found,
as expected, in tissues with a lot of proliferative cells, such as spleen, testis, and thymus (Table S1).
TAA expression was also assessed on a small selection of commercially available gynecological
tumor cell lines. All TAA were expressed at medium to high levels in these cell lines, except for
MAGE-A3, which showed lower expression levels (Table S1).
2.2. TAA Expression in Uterine Cancer at mRNA Level
When looking at the mRNA expression levels of BORIS in our sample collection, we noted that
BORIS was detectable in 60% of healthy controls, 50% of endometrial carcinomas and 92% of uterine
sarcomas. Furthermore, we observed BORIS overexpression (calculated as >2-fold increase compared
with the mean expression in healthy controls) in 26% of endometrial carcinomas and 62% of uterine
sarcomas (Table 1). The expression seems slightly, yet not significantly, increased in uterine sarcoma
(US) compared with endometrial carcinoma (EMCAR; Figure 1A). Due to a fairly small amount of
samples tested for this antigen, no analysis concerning clinicopathological features was performed.
All clinicopathological features of the samples that were currently analyzed are summarized in Table S2.
Table 1. Evaluation of TAA expression in patient biopsies by qRT-PCR.
TAA 1 Samples
Healthy
Controls
Endometrial
Carcinoma Uterine Sarcoma
BORIS 2
# 3 samples tested (% 4) 9 (100) 49 (100) 15 (100)
# evaluable samples (%) 5 5 (56) 43 (88) 13 (87)
# undetectable samples (%) 6 2 (40) 21 (50) 1 (8)
% >2-fold change 7 (%) 11 (26) 8 (62)
MAGE-A3 8
# samples tested (%) 12 (100) 71 (100) 35 (100)
# evaluable samples (%) 5 10 (83) 70 (99) 34 (97)
# undetectable samples (%) 6 0 (0) 7 (10) 3 (9)
% >2-fold change 7 7 (10) 3 (9)
Sp17 9
# samples tested (%) 12 (100) 71 (100) 34 (100)
# evaluable samples (%) 5 10 (83) 70 (99) 34 (100)
# undetectable samples (%) 6 0 (0) 0 (0) 0 (0)
% >2-fold change 7 14 (20) 1 (3)
hTERT 10
# samples tested (%) 9 (100) 70 (100) 34 (100)
# evaluable samples (%) 5 9 (100) 70 (100) 33 (97)
# undetectable samples (%) 6 6 (67) 0 (0) 26 (79)
% >2-fold change 3 50 (71) 16 (48)
1 tumor-associated antigen; 2 brother of the regulator of imprinted sites; 3 Number; 4 Percentage; 5 A sample is
considered evaluable if the Ct of the reference genes is below 30; 6 A sample is considered undetectable when
no Ct value could be measured (i.e., Ct > 40); 7 Numbers are expressed as >2-fold change compared to the
mean expression of normal endometrium; 8 melanoma-associated antigen A3; 9 Sperm protein 17; 10 human
telomerase reverse transcriptase.
MAGE-A3 could be detected in almost all samples (100% of controls, 90% EMCAR and 91% US)
and was overexpressed at mRNA level in 10% of EMCAR samples and 9% of US samples (Table 1,
Figure 1B). No differences in MAGE-A3 expression were observed among the different FIGO stages
of EMCAR, nor between the different histological subtypes or grade of differentiation of EMCAR or
histological subtypes of US (data not shown).
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Figure 1. mRNA expression of TAA in uterine tumors: (A) BORIS expression; (B) MAGE-A3;  
(C) Sp17; and (D) hTERT. Results are expressed as fold change compared to the mean normalized 
expression of normal endometrium. Overexpression is defined as two-fold increase compared to 
normal endometrium (dashed line). TAA: tumor-associated antigen; EMCAR: endometrial 
carcinoma; US: uterine sarcoma; BORIS: brother of the regulator of imprinted sites; MAGE-A3: 
melanoma-associated antigen A3; Sp17: sperm protein 17; hTERT: human telomerase reverse 
transcriptase; * p < 0.05. 
Sp17 transcripts could be detected in all samples. Overexpression of Sp17 mRNA was found in 
20% of samples of the EMCAR population and in 3% of uterine sarcomas (Table 1). It was significantly 
up-regulated in EMCAR compared with US (p = 0.0273, Figure 1C). In addition, a significant down-
regulation in type II EMCAR compared with type I EMCAR was found (p = 0.0206), indicating 
potential down-regulation of Sp17 with increased aggressiveness of tumors (data not shown). 
We noted that hTERT was detectable in 33% of control samples, 100% of EMCAR and 21% of US 
samples. hTERT mRNA was overexpressed in 71% and 48% of EMCAR and US, respectively (Table 1, 
Figure 1D). When comparing hTERT expression in EMCAR according to FIGO stage, hTERT was  
up-regulated in stages II (p < 0.01), III (p < 0.01) and IV (p < 0.05) compared to stage I (data not shown). 
2.3. TAA Expression in Normal Human Tissues at Protein Level 
Protein analysis was done only for hTERT and MUC1. For the other antigens, no optimal specific 
antibody was available. For MAGE-A3 there is no commercially available antibody that is specific for 
the detection of MAGE-A3; TAA expression in normal tissues was evaluated using a TMA containing 
22 different normal tissues. We found that 42.9% expressed MUC1. As expected, expression was 
predominantly found in epithelial cells. In addition, 57.6% of tissues expressed hTERT. The tissues 
that express each of the investigated antigens and the respective scores are summarized in Table S3. 
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Sp17 tr nscripts could be detected i all samples. Overexpression of Sp17 mRNA was
found in 20% of samples of the EMCAR population and in 3% of uterine sarcomas (Table 1).
It was significantly up-regulated in EMCAR compared with US (p = 0.0273, Figure 1C). In addition,
a significant down-regulation in type II EMCAR compared with type I EMCAR was found
(p = 0.0206), indicating potential down-regulation of Sp17 with increased aggressiveness of tumors
(data not shown).
We noted that hTERT was detectable in 33% of control samples, 100% of EMCAR and 21% of US
samples. hTERT mRNA was overexpressed in 71% and 48% of EMCAR and US, respectively (Table 1,
Figure 1D). When comparing hTERT expression in EMCAR according to FIGO stage, hTERT was
up-regulated in stages II (p < 0.01), III (p < 0.01) and IV (p < 0.05) compared to stage I (data not shown).
2.3. TAA Expression in Normal Human Tissues at Protein Level
Protein analysis was done only for hTERT and MUC1. For the other antigens, no optimal specific
antibody was available. For MAGE-A3 there is no commercially available antibody that is specific for
the detection of MAGE-A3; TAA expression in normal tissues was evaluated using a TMA containing
22 different normal tissues. We found that 42.9% expressed MUC1. As expected, expression was
predominantly found in epithelial cells. In addition, 57.6% of tissues expressed hTERT. The tissues
that express each of the investigated antigens and the respective scores are summarized in Table S3.
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2.4. TAA Expression in Uterine Cancer at Protein Level
For protein expression analysis of MUC1 and hTERT a broad spectrum of paraffin-embedded
tissue samples were analyzed. A representative picture of a negative, weak and intense staining pattern
of MUC1 and hTERT is shown in Figure 2. All clinicopathological characteristics are summarized in
Table S4. In addition, in order to obtain an idea on the expression of a certain antigen in the tumor as
a whole, specimens taken at different locations in the tumor, to a maximum of three different sites,
were analyzed if possible. The total number of tumors that were analyzed for each of the antigens is
summarized in Table 2.
Int. J. Mol. Sci. 2016, 17, 1525 5 of 18 
 
2.4. TAA Expression in Uterine Cancer at Protein Level 
For protein expression analysis of MUC1 and hTERT a broad spectrum of paraffin-embedded 
tissue samples were analyzed. A representative picture of a negative, weak and intense staining 
pattern of MUC1 and hTERT is shown in Figure 2. All clinicopathological characteristics are 
summarized in Table S4. In addition, in order to obtain an idea on the expression of a certain antigen 
in th  tumor as a whole, specim ns taken at different locati ns in the tu or, to a maximum of three 
different sites, were analyzed if possible. The total number of tumors that were analyzed for each of 
the ntigens is summarized in Table 2. 
 
Figure 2. Immunohistochemical staining of MUC1 and hTERT in uterine cancer tissues. In this picture, 
we show a representative picture of a negative, weak and strong staining pattern for both antigens. 
Pictures were taken at a 10× magnification. 
Microscopic analysis of the tissue samples showed that for MUC1, 96.6% of the pooled EMCAR 
population expressed the antigen. In comparison with normal endometrium, primary tumors  
(p < 0.05) as well as recurrent tumors (p < 0.01) and metastatic lesions (p < 0.01) show a significant  
up-regulation (Figure 3A) based on slide scoring. In addition, 43% of the US samples was also positive 
for this tumor antigen. For this type of tumors, the metastatic lesions show a significant up-regulation 
of MUC1 in comparison to the primary and recurrent tumors (p < 0.05; Figure 3A). This difference is 
most likely due to the high total amount of carcinosarcomas and endometrial stromal sarcomas in 
the total population of metastases (9/13). However, in the recurrent tumor population 8/13 tumors 
have either histological subtype, indicating that MUC1 is indeed expressed at the highest level in 
metastatic lesions. For a small number of patients, we had paired biopsies of the primary tumor 
and/or metastatic tumor and/or recurrent tumor in our data collection for which the scores are  
shown in Table S5. In addition, these data point to an upregulation of MUC1 in metastatic and 
recurrent tumors, although this analysis has to be interpreted with caution due to the limited number 
of patients. 
The protein data for hTERT showed positivity in 75.6% of EMCAR samples and in 59.3% of  
US samples. Remarkably, the antigen was significantly up-regulated in normal endometria in 
comparison to primary EMCAR and metastatic EMCAR locations (p < 0.05) as well as primary and 
recurrent US (p < 0.01, Figure 3B). In addition, for hTERT, we show in Table S5 the scores of the IHC 
staining in a small number of patients with paired biopsies of primary and/or metastatic and/or 
recurrent tumors. However, since the hTERT stained section of the primary tumors of two of these 
eight patients were impossible to score due to extensive tissue breakdown, no conclusions could  
be drawn. 
  
Figure 2. Im unohistochemical staining of in uterine cancer tissues. In this picture,
we show a representative picture of a negative, eak a strong staining pattern for both antigens.
Pictures were taken at a 10× agnification.
Microscopic analysis of the tissue samples showed that for MUC1, 96.6% of the pooled EMCAR
population expressed the antigen. In comparison with normal endometrium, primary tumors (p < 0.05)
as well as recurrent tumors (p < 0.01) and metastatic lesions (p < 0.01) show a significant up-regulation
(Figure 3A) based on slide scoring. In addition, 43% of the US samples was also positive for this
tumor antigen. For this type of tumors, the metastatic lesions show a significant up-regulation of
MUC1 in comparison to the primary and recurrent tumors (p < 0.05; Figure 3A). This difference is
most likely due to the high total amount of carcinosarcomas and endometrial stromal sarcomas in
the total population of metastases (9/13). However, in the recurrent tumor population 8/13 tumors
have either histological subtype, indicating that MUC1 is indeed expressed at the highest level in
metastatic lesions. For a small number of patients, we had paired biopsies of the primary tumor and/or
metastatic tumor and/or recurrent tumor in our data collection for which the scores re shown in
Table S5. In addition, ese data point to an upregulation of MUC1 in metastatic and recurre t tumors,
although this analysis has to be interpreted with caution due to the limited number of patients.
The protein dat for hTERT showed positivity in 75.6% of EMCAR samples and in 59.3% of US
samples. Remarkably, the antigen was significantly up-regulated in normal endo etria in comp rison
to primary EMCAR and metastatic EMCAR locations (p < 0.05) as well as primary and recurrent US
(p < 0.01, Figure 3B). In addition, for hTERT, we show in Table S5 the scores of the IHC staining in a
small number of patients with paired biopsies of primary and/or metastatic and/or recurrent tumors.
However, since the hTERT stained section of the primary tumors of two of these eight patients were
impossible to score due to extensive tissue breakdown, no conclusions could be drawn.
Int. J. Mol. Sci. 2016, 17, 1525 6 of 19
Table 2. Evaluation of TAA expression in patient biopsies by IHC.
Tumor Type
MUC1 hTERT
#1 Samples %2 Positive # Samples % Positive
Normal tissue 17 82.4 14 92.8
Primary carcinoma 48 91.6 30 66.7
Recurrent carcinoma 11 100 10 90
Metastatic carcinoma 10 90 9 66.7
Primary sarcoma 39 33.3 22 50
Recurrent sarcoma 15 26.7 12 41.7
Metastatic sarcoma 13 69.2 13 76.9
1 Number of analyzed samples; 2 percentage of positive samples; IHC: immunohistochemistry.
Int. J. Mol. Sci. 2016, 17, 1525 6 of 18 
 
Table 2. Evaluation of TAA expression in patient biopsies by IHC. 
Tumor Type 
MUC1 hTERT 
#1 Samples %2 Positive # Samples % Positive
Normal tissue 17 82.4 14 92.8 
Primary carcinoma 48 91.6 30 66.7 
Recurrent carcinoma 11 100 10 90 
Metastatic carcinoma 10 90 9 66.7 
Primary sarcoma 39 33.3 22 50 
Recurrent sarcoma 15 26.7 12 41.7 
Metastatic sarcoma 13 69.2 13 76.9 
1 Number of analyzed samples; 2 percentage of positive samples; IHC: immunohistochemistry. 
 
Figure 3. Expression levels of TAA by IHC: (Left) overall percentage of positive biopsies;  
(Middle) TAA expression levels in normal endometrium and EMCAR samples; and (Right) TAA 
expression levels in normal endometrium and US samples. (A) MUC1 expression; and (B) hTERT 
levels. nl EM: normal endometrium; pr EMCAR: primary endometrial carcinoma; rec EMCAR: 
recurrent endometrial carcinoma; meta EMCAR: metastasis endometrial carcinoma; pr US: primary 
uterine sarcoma; rec US: recurrent uterine sarcoma; meta US: metastasis uterine sarcoma. * p < 0.05;  
** p < 0.01. 
For all the currently described antigens, no sub-analysis was done to determine differences in 
expression according to clinicopathological characteristics, due to too small sample sizes to perform 
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2.5. Endogenous T Cell Responses to TAA 
MAGE-A3, MUC1, Sp17 and hTERT were selected for further assessment of immunogenicity by 
determining the presence of endogenous TAA-specific T cells after stimulation with overlapping 
peptides covering the whole TAA. Stimulation with peptide pools covering the viral antigens 
CMVpp65, EBV BZLF1 and Influenza Matrix Protein 1 were included as a control for assessing 
immune competence. CD137 up-regulation on CD4+ and CD8+ T cells after in vitro culture of PBMC 
with the indicated peptide pools was measured. The clinical characteristics of the patients included 
in this analysis are shown in Table S6 and the raw data of the T cell responses are shown in Table S7. 
Figure 3. Expression levels of TAA by IHC: (Left) overall percentage of positive biopsies; (Middle) TAA
expression levels in normal endometrium and EMCAR samples; and (Right) TAA expression levels in
normal endometrium and US samples. (A) MUC1 expression; and (B) hTERT levels. nl EM: normal
endometrium; pr EMCAR: primary endometrial carcinoma; rec EMCAR: recurrent endometrial
carcinoma; meta EMCAR: metastasis endometrial carcinoma; pr US: primary uterine sarcoma;
rec US: recurrent uterine sarcoma; meta US: metastasis uterine sarcoma. * p < 0.05; ** p < 0.01.
For all the currently described antigens, no sub-analysis was done to determine differences in
expression according to clinicopathological characteristics, due to too small sample sizes to perform
sound analyses.
2.5. Endogenous T Cell Responses to TAA
MAGE-A3, MUC1, Sp17 and hTERT were selected for further assessment of immunogenicity by
determining the presence of endogenous TAA-specific T cells after stimulation with overlapping
peptides covering the whole TAA. Stimulation with peptide pools covering the viral antigens
CMVpp65, EBV BZLF1 and Influenza Matrix Protein 1 were included as a control for assessing
immune competence. CD137 up-regulation on CD4+ and CD8+ T cells after in vitro culture of PBMC
with the indicated peptide pools was measured. The clinical characteristics of the patients included in
this analysis are shown in Table S6 and the raw data of the T cell responses are shown in Table S7.
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Virus-specific immunity as determined by CD137 up-regulation on either CD4+ or CD8+ T cells
upon stimulation with at least 1 of the 3 viral antigens was observed in 7/9 (77.8%) of benign controls,
29/31 (93.5%) of EMCAR patients and 14/15 (93.3%) of US patients (data not shown). In Figure 4,
we show representative dot plots of the flow cytometric data of two patient samples.
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Figure 4. Flow cytometric analysis of antigen-specific T cell responses. For two patients, 
representative dot plots are shown of CD4+CD137+ and CD8+CD137+ T cells after ex vivo stimulation 
with the indicated overlapping peptide pools. Cells are gated on either CD3+CD4+CD8−CD19− cells or 
on CD3+CD4−CD8+CD19− cells within the live PBMC gate, as described in the Experimental Section 
and as depicted in Figure S1. 
Figure 4. Flow cytometric analysis of antigen-specific T cell responses. For two patients, representative
dot plots are shown of CD4+CD137+ and CD8+CD137+ T cells after ex vivo stimulation with the
indicated overlapping peptide pools. Cells are gated on either CD3+CD4+CD8−CD19− cells or on
CD3+CD4−CD8+CD19− cells within the live PBMC gate, as described in the Experimental Section and
as depicted in Figure S1.
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MAGE-A3 specific T cells could be measured in 2/9 controls for CD4+ T cells and 2/9 controls
for CD8+ T cells. For EMCAR patients, MAGE-A3 specific CD4+ and CD8+ T cells were observed in
3/31 and 4/31 patients, respectively, while for US patients MAGE-A3 reactivity could be noted in
6/15 patients for CD4+ T cells and in 4/15 patients for CD8+ T cells (Figure 5A).
MUC1 specific CD4+ and CD8+ T cells were present in 2/9 controls for CD4+ T cells and in
1/9 controls for CD8+ T cells. For EMCAR patients, MUC1 responsiveness could be observed in CD4+
T cells in 5/31 patients and in CD8+ T cells in 1/31 patients. In US, MUC1 specificity was measured in
1/15 patients for CD4+ T cells and in 3/15 patients for CD8+ T cells (Figure 5B).
For Sp17, control patients showed no reactivity for either CD4+ or CD8+ T cells. In EMCAR,
Sp17 specificity was seen in 2/31 patients for CD4+ T cells, while Sp17 specific T cells could be noted
in 1/15 and 2/15 US patients for CD4+ and CD8+ T cells, respectively (Figure 5C).
hTERT specific T cells were detected in 2/4 and 1/4 control patients for CD4+ and CD8+ T cells,
respectively. In EMCAR patients, hTERT specific T cells were measured in 9/16 patients for CD4+ T
cells and in 10/16 patients for CD8+ T cells. Finally, hTERT reactivity was noted in 3/6 US patients for
both CD4+ and CD8+ T cells (Figure 5D).
Int. J. Mol. Sci. 2016, 17, 1525 8 of 18 
 
MAGE-A3 specific T cells could be measured in 2/9 controls for CD4+ T cells and 2/9 controls for 
CD8+ T cells. For EMCAR patients, MAGE-A3 specific CD4+ and CD8+ T cells were observed in 3/31 
and 4/31 patients, respectively, while for US patients MAGE-A3 reactivity could be noted in 6/15 
patients for CD4+ T cells and in 4/15 patients for CD8+ T cells (Figure 5A). 
MUC1 specific CD4+ and CD8+ T cells were present in 2/9 controls for CD4+ T cells and in 1/9 
controls for CD8+ T cells. For EMCAR patients, MUC1 responsiveness could be observed in CD4+ T 
cells in 5/31 patients and in CD8+ T cells in 1/31 patients. In US, MUC1 specificity was measured in 
1/15 patients for CD4+ T cells and in 3/15 patients for CD8+ T cells (Figure 5B). 
For Sp17, control patients showed no reactivity for either CD4+ or CD8+ T cells. In EMCAR, Sp17 
specificity was seen in 2/31 patients for CD4+ T cells, while Sp17 specific T cells could be noted in 1/15 
and 2/15 US patients for CD4+ and CD8+ T cells, respectively (Figure 5C). 
hTERT specific T cells were detected in 2/   4 control patients for CD4+ and CD8+ T cells, 
respectively. In EMCAR patients, hTERT specific T cells were measured in 9/    +  
T cells a d in 10/16 patients for CD8+ T cells. Finally, hTERT react vity was noted in 3/6 US patients 
for both CD4+ and CD8+ T cells (Figure 5D). 
 
Figure 5. Analysis of T cell responses: (A) CD4+ and CD8+ responses against MAGE-A3; (B) CD4+ and 
CD8+ responses against MUC1; (C) CD4+ and CD8+ responses against Sp17; and (D) CD4+ and CD8+ 
responses against hTERT. 
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Figure 5. Analysis of T cell responses: (A) CD4+ and CD8+ responses against MAGE-A3; (B) CD4+ and
CD8+ responses against MUC1; (C) CD4+ and CD8+ responses against Sp17; and (D) CD4+ and CD8+
responses against hTERT.
Altogether, endogenous T cells specific to any of the tested TAA were only detected in a minority
of patients, except towards hTERT where we noted T cell responses in almost half of the patients
tested. When looking at all tested antigens, 44% of control patients and 54% of uterine cancer patients
showed a T cell response to any of the tested antigens. Furthermore, 22% of control patients and 30%
of uterine cancer patients showed a response towards two or more tumor antigens. For some of the
tested patients, we investigated whether levels of TAA specific T cells correlate ith TAA expression
levels in the tumor but we could not note a correlation for any TAA (data not shown).
3. Discussion
We have curr tly validated the expression of five different a tigens in uterine tumors,
comprising both endometrial carcinoma and uterine sarcoma. To our knowl dge, this is the first study
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to describe the presence of these antigens in uterine sarcoma, with the exception of BORIS [31]. Since the
immunogenicity of an antigen, i.e., the ability to elicit an immune response is a key characteristic in
order for the antigen to be eligible as a target for immunotherapy, we also assessed whether uterine
cancer patients harbored endogenous TAA-specific T cells in their blood. Spontaneous T cell responses
against several TAA, mainly melanoma-associated antigens, have been described in several tumor
types, both solid tumors and hematological tumors [32]. To our knowledge, spontaneous T cell
responses to any of the tested TAA in this study have not been reported to date in either endometrial
carcinoma or uterine sarcoma. Furthermore, most studies assessed the immunogenicity to selected
TAA-derived peptides in the context of certain MHC molecules, while we used overlapping 15 amino
acid peptides covering the whole TAA to overcome MHC restriction and to measure both CD4+
and CD8+ T cell responses. For most TAA, only low levels of T cell responses could be detected,
but we emphasize that this might be due to the experimental conditions used: TAA-specific T cell
responses were tested directly ex vivo, without further in vitro restimulation. Thus, the fact that no
TAA-specific T cells could be detected in a certain patient does not preclude that TAA-specific T cell
precursors are not present, but they might be below the detection limit in these experimental conditions
and could become detectable upon long-term in vitro stimulation.
BORIS is a TAA that has emerged fairly recent and has been investigated in several tumor
types [33]. BORIS was described in uterine cancer by Risinger et al. [31], to which our results do not
entirely correspond. Using a different primer set, they have shown expression in 77% of EMCAR and
no expression in normal endometrium. A recent study concerning the expression of BORIS and its
paralog CTCF in EMCAR showed that BORIS RNA was significantly increased in non-endometrioid
tumors compared with endometrioid tumors [34]. In addition, BORIS levels increased during cancer
progression and was associated with aggressive tumors. Importantly, there was an association between
BORIS expression and worse five-year disease-free survival. To our knowledge, BORIS-targeted
immunotherapy has not been described in the clinic, although a DC vaccine loaded with a truncated
form of BORIS has shown promise in the 4T1 mammary mouse tumor model [35].
MAGE-A3 is a cancer-testis antigen that has extensively been studied, both in preclinical models
as in the clinic. In contradiction to previously published results by Chitale et al. [36], who found
MAGE-A3 to be present in 20% of the analyzed 130 endometrial cancers, we found MAGE-A3 to be
present in 90% of the analyzed tumor biopsies, but overexpressed compared to normal endometrium
in only 10% of cases. Chitale et al. performed their analysis based on a TMA applying a threshold
for positivity of protein expression in >50% of tumor cells, while we currently analyzed the presence
of mRNA encoding for MAGE-A3, which allows for the detection of lower levels of TAA expression.
MAGE-A3 specific T cells could only be detected in a limited number of patients, which might be due
to the very low frequency of MAGE-A3 specific T cells in circulation that may not be detectable with the
method used in our study. Inokuma et al. previously showed low level MAGE-A3 T cell responses in
healthy females which were increased in breast cancer patients [37], which corroborates our finding of
spontaneous MAGE-A3 specific T cells in patients with benign diseases. Our currently analyzed patient
population is however too small to evaluate whether these responses are increased in endometrial
carcinoma or uterine sarcoma. MAGE-A3 vaccination has a long history in the clinic, especially in
melanoma and NSCLC, but although immune responses are frequently induced, clinical effects have
been disappointing and have led to the discontinuation of two major phase III clinical trials by GSK
due to lack of efficacy. However, due to its interaction with p53 proteins and its expression in cancer
stem cells, MAGE-A3 continues to be pursued as an immunotherapeutic approach [38].
Sp17 is a cancer-testis antigen described to be expressed by several tumor types. The percentage of
tumors expressing Sp17 in our study is higher than found by Li et al. [39]. However, Li et al. analyzed
Sp17 protein expression, which may explain the discrepancy. It may indicate that, even though present
as mRNA, it may possibly not be translated into a functional protein in the majority of cases. Next to
its presence in uterine tumors, Sp17 has also been shown in ovarian tumors [40,41]. Sp17 RNA was
detected in 83% of ovarian tumors. In addition, Sp17 has been shown to be related to chemoresistance
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in ovarian cancer. Spontaneous Sp17 specific T cells have, to our knowledge, not been described to date,
neither in healthy donors, nor in cancer patients. The group of Chiriva-Internati, however, has shown
that it is possible to generate Sp17 specific T cells after four rounds of in vitro stimulations with
Sp17-pulsed DC in patients with ovarian cancer and multiple myeloma and in healthy donors [42–44].
These data suggest the presence of low levels of Sp17 specific T cells in the circulation of both healthy
donors and cancer patients. To our knowledge, Sp17-targeted immunotherapeutic approaches have
not been tested yet in the clinic, although DC transduced with an adenovirus encoding Sp17 could
induce Sp17-specific T cells in vitro that were capable of killing NSCLC tumor cells [45].
MUC1 has been a long time pursued as an immunological target. Our results shown a higher
percentage of MUC1-positive tumors with respect to previously published data [46]. MUC1 has been
described to play a role in tissue invasion of tumor cells and the formation of metastases [47–49].
In our data, we show that there is an increase in MUC1 expression level when comparing normal
endometrial samples to primary carcinoma samples as well as to recurrent EMCAR and metastatic
lesions, further supporting these data. In US samples, we found MUC1 expression in 43% of
tumors. This is unexpected since MUC1 is an epithelial antigen and sarcomas are of mesenchymal
origin. Our current tumor population, however, also contains malignant mixed mesodermal tumors,
also known as carcinosarcomas, endometrial stromal sarcomas, and adenosarcomas, which both
contain an epithelial component where MUC1 is present. Although the majority of the positive
sarcomas are attributable to these two types of tumors, we did find other sarcomatous tumors to be
positive for MUC1. The presence of pre-existing MUC1 specific T cell immunity in both healthy donors
as well as breast cancer patients has been described by Gückel et al., which corroborates our findings
of MUC1 reactive T cells in patients with benign diseases [50]. MUC1 targeted immunotherapy has a
long clinical experience and has proven to be safe, with a lack of autoimmune responses. However,
clinical efficacy is still lacking but the focus is now shifting to the application of MUC1 immunotherapy
in the right circumstances, such as combination with chemoradiotherapy and combination with
immune checkpoint inhibitors [51].
Telomerase was chosen as target to evaluate due to its role in tumor cell proliferation and survival.
hTERT was found to be present in its RNA form in 100% of analyzed EMCAR samples. These results
are comparable to previously published results, showing its expression in 78% [52] and 92% [53] of
EMCAR samples. The current mRNA and protein data for hTERT expression do not correspond
entirely. Although some of the expression levels we found in normal tissue were similar to previously
described expression levels [54], we found high hTERT protein expression in brain, kidney, prostate,
pancreas and liver, and a negative result for testis tissue. This is quite unexpected and in contradiction
to the results of Hiyama et al., and Kyo et al. [52,54]. In addition, we found hTERT protein to be
higher in normal endometrial samples compared to EMCAR and US. This phenomenon cannot
not be explained solely by hTERT expression in proliferative endometrium, as we also found clear
expression in atrophic endometrium, contradicting previous results [55]. These results led us to
suspect that the antibody that was used for the immunohistochemistry is likely not ideal. mRNA data
showed that hTERT is overexpressed in 71% of tumors compared with normal endometrium and we
found an up-regulation in more advanced tumors, supporting the role of hTERT in immortalization
and tumor development. hTERT was expressed both as mRNA transcript and protein in sarcoma
samples. In addition, we found a significant down-regulation of hTERT in primary and recurrent
US in comparison to normal endometrium. In our patient population, vigorous T cell responses
to hTERT could be detected. Endogenous T cell responses towards hTERT have been described by
several groups in different tumor types and the reported results are quite heterogeneous with regard
to the proportion of patients with detectable immunity and the presence of hTERT specific T cells in
healthy donors [56–63]. Most studies used only 1 or a few HLA restricted peptides, which considerably
constricts the chance of detecting specific T cells. The studies also differed in whether T cells were
tested directly ex vivo or first restimulated with peptides in vitro before assessing hTERT reactivity.
However, overall these studies are in agreement with our study in that hTERT specific T cells are
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present in the T cell repertoire of cancer patients. Furthermore, clinical trials with hTERT-targeting
vaccines have demonstrated that specific immune responses are induced by these vaccines without
major toxicity [64]. Yet, there has been a report of a study in mice by Ugel et al. [65] that showed
the development of autoimmune B cell lymphopenia after adoptive transfer of hTERT specific T
cells, which was however a temporary phenomenon. Although clinical trials of immunotherapy with
hTERT-based vaccines have demonstrated only modest clinical benefit, an optimized vaccine design,
more rational patient selection (based on novel insights on hTERT promoter mutations and genomic
rearrangements proximal to hTERT) and combination with immune checkpoint inhibitors might offer
novel opportunities for hTERT-targeted vaccination [66].
Keeping in mind the recent emergence of mutation-derived neoantigens as targets for
immunotherapy, we believe that any future immunotherapeutic approach should also target these
antigens. Our study was initiated before the description of the immunogenicity of neoantigens,
but their value has been definitely described in POLE-mutated and MSI endometrial tumors [26].
However, the identification of neoantigens is still a cumbersome, time-consuming and expensive
approach. Therefore, we propose to use whole-tumor derived approaches for tumor vaccination in
uterine cancer, which would target both shared TAA as well as neoantigens. Whole tumor lysate or
amplified whole tumor mRNA could be used to load onto DC or nanoparticles for vaccination [67].
Alternatively, tumor-infiltrating lymphocytes (TIL) isolated from uterine tumors and expanded ex vivo
are also expected to contain reactivity to both shared TAA and neoantigens [68,69]. Thus, TIL therapy
could also be a promising approach for uterine cancers.
In conclusion, the current data collectively validate the presence of the selected TAA in
endometrial cancer and indicate the presence of those antigens in uterine sarcoma. In addition,
spontaneous T cell responses could be detected in patient blood, indicating the immunogenicity of these
antigens. Based on the combined analysis of TAA expression data and the occurrence of TAA-specific
T cells, MUC1 and hTERT show the best profile for future application in immunotherapeutic studies,
along with the previously validated survivin [70]. However, due to the emergence of neoantigens for
cancer immunotherapy, we suggest whole tumor-targeted approaches as optimal vaccination strategies
in uterine cancer.
4. Experimental Section
4.1. Patient Samples, Cell Lines and Reagents
Biopsy material from uterine cancer patients and healthy controls was collected from the tissue
biobank of the gynecologic oncology department at the University Hospital Leuven. Whole blood
was collected from uterine cancer patients or patients with benign gynecological diseases through
venipuncture using EDTA-coated BD vacutainer tubes (BD Diagnostics, Erembodegem, Belgium);
buffy coats of healthy controls, collected in ACD bags, were purchased from the Belgian Red Cross.
Freshly collected blood was stored at room temperature and processed within 24 h.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
approved by the Ethics Committee of University Hospitals Leuven. Informed consent was obtained
from all patients donating blood and/or tumor tissue prior to inclusion in the study.
Expression levels in normal tissues were analyzed using RNA isolated from normal tissues,
purchased from Ambion (Life Technologies, Gent, Belgium) and/or a tissue microarray (TMA)
(Pantomics, Inc., Richmond, CA, USA).
The commercial cell lines SKOV-3, OVCAR-3, RL-95-2, HEC-1 and SK-UT-1 were obtained from
ATCC (Manassas, VA, USA).
Peptide pools consisting of 15-mer peptides with an 11 aa overlap were obtained from
Miltenyi Biotec (Leiden, The Netherlands, MAGE-A3, hTERT, CMVpp65, EBV BZLF1 and Influenza
MP1), JPT Peptide Technologies GmbH (Berlin, Germany, MUC1, VNTR repeat region, custom made)
or Thermo Scientific (Gent, Belgium, Sp17, custom made).
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4.2. RNA Isolation and Reverse Transcription Reaction
Total RNA was isolated from snap-frozen material using Trizol (Life Technologies), according to
manufacturer’s instructions. 0.2 µg RNA was reverse-transcribed in a total volume of 20 µL in a mixture
containing 10X RT buffer, 5.5 mM MgCl2, 10 mM dNTP’s, 2.4 µM random hexamers, 0.5 U/µL RNase
inhibitor and 50 U/µL Multiscribe reverse transcriptase (all from Life Technologies). The reaction was
performed using ABI prism® 7000 Sequence Detection System (Life Technologies) as follows: 10 min
at 25 ◦C, 30 min at 48 ◦C and 5 min at 95 ◦C.
4.3. Quantitative Real-Time PCR
Quantitative real-time PCR (qRT-PCR) was performed by using ABI prism® 7000 Sequence
Detection System (Life Technologies) and the data were analyzed with 7000 system software.
Tumor cDNA was analyzed together with testis cDNA as positive control. qRT-PCR reactions were
performed in triplicate for all samples. Thermal cycling conditions were as follows: 2 min at 50 ◦C,
10 min at 95 ◦C and 40 cycles of 15 s at 95 ◦C and 1 min at 60 ◦C. Primers used for the different genes
are indicated in Table 3.
Table 3. Primers used for qRT-PCR.
TAA Primers and Probe
BORIS Human CTCFL Taqman gene expression assay from Applied Biosystems (Life Technologies)
MAGE-A3
Sense primer, 5′-GTCGTCGGAAATTGGCAGTAT-3′
Antisense primer, 5′-GCAGGTGGCAAAGATGTACAA-3′
Probe, 5′-6FAM-AAAGCTTCCAGTTCCTT-MGB-3′
Sp17 Human SPA17 Taqman gene expression assay from Applied Biosystems (Life Technologies)
hTERT Human TERT Taqman gene expression assay from Applied Biosystems (Life Technologies)
β-actin Human ACTB (beta actin) Endogenous Control from Applied Biosystems (Life Technologies)
β-glucuronidase Human GUSB (beta glucuronidase) Endogenous Control from Applied Biosystems (Life Technologies)
TAA gene expression levels were normalized to the geometric mean of β-actin and
β-glucuronidase and the mean normalized expression (MNE) was calculated with Q-Gene software.
Samples in which cycle threshold (Ct) values of housekeeping genes (β-actin and β-glucuronidase)
were above 30 were considered to be of insufficient quality and omitted from analysis. Samples in which
no Ct value for a gene of interest could be measured were considered undetectable (i.e., no expression).
All PCR data were expressed as fold change compared to the mean MNE of normal endometrium
samples. TAA were considered to be overexpressed in case of ≥2-fold increase. Statistical analysis
to calculate differences in expression levels between groups were performed with GraphPad Prism
(La Jolla, CA, USA) software, using the appropriate (non)-parametric test following initial analyses to
determine normal distribution of results using the D′Agostino and Pearson omnibus normality test.
4.4. Immunohistochemistry
For all stainings, 4.0 µm phormol-fixed, paraffin-embedded tissue sections were stained.
Sections were first deparaffinized and rehydrated in ethanol. Next, endogenous peroxidase was
blocked in 0.5% (MUC1) or 3% H2O2 (hTERT) in methanol for 30 min. For hTERT, heat-induced
epitope retrieval (HIER) was performed at 85 ◦C. For MUC1, the same step was performed for 1 h at
90 ◦C in citrate (pH 6.0), after which the slides were cooled down and primary antibody incubation
was performed. Ms α Hu MUC1 (DAKO, Heverlee, Belgium, M0613; 1.15 µg/mL) incubated for 2 h at
room temperature (RT). Rb anti Hu TERT (Rockland Inc., Limerick, PA, USA, 600-401-252; 2.5 µg/mL)
incubated overnight at 4 ◦C. For all antigens, EnVision+ system HRP-labelled polymers (DAKO) were
used as secondary antibodies and incubated for 30 min at RT. Visualization was performed using
3,3′-Diaminobenzidine (DAB, Sigma-Aldrich, Diegem, Belgium) and hematoxylin counterstaining.
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The validation of the tumor associated antigens on normal tissues was done using a tissue
microarray (TMA) (MTU951; Pantomics, Inc.), following the same protocols.
4.5. Slide Scoring
For evaluation of antigen expression, a scoring system was developed based on 2 different
parameters: percentage of tumor cells staining positive for the antigen and the staining intensity.
For each parameter, 3 different levels were determined. The percentage of tumor cells staining positive
was divided in 1%–25%, 25%–50% and >50%. The staining intensity was evaluated as weak (score 1),
moderate (score 2) and strong (score 3). Based on these parameters a total score was assigned to each
slide (Table 4). All slides were analyzed for the presence of tumor using a conventionally stained
HE slide.
Table 4. Scoring system for evaluation of TAA expression by IHC.
Percent Positive Tumor Cells Staining Intensity Assigned Score
1–25 1 0
1–25 2 0
1–25 3 0
25–50 1 0
25–50 2 1+
25–50 3 2+
>50 1 0
>50 2 3+
>50 3 4+
4.6. PBMC Isolation
For healthy donors, buffy coats were diluted 1/3 in PBS and PBMC were isolated using
Lymphoprep™ (AXIS-SHIELD, Dundee, Scotland) density gradient centrifugation according to
manufacturer’s instructions and counted with Türck’s solution (Millipore, Overijse, Belgium).
For patient samples, peripheral blood was diluted 1/2 in PBS and isolated following the same protocol.
The median PBMC number obtained was 8.5× 106 cells per 10 mL of whole patient blood. PBMC were
cryopreserved in 90% human AB serum (Sera Laboratories International, West Sussex, UK) containing
10% DMSO at (5–10) × 106 cells per vial using CoolCell freezing containers (BioCision, San Rafael, CA,
USA). The freezing container was placed at −80 ◦C and vials were transported to liquid nitrogen after
16–48 h and stored until further use.
4.7. Detection of TAA-Specific T Cells
The CD137 assay was carried out in T cell medium (IMDM (Life Technologies) supplemented with
5% human AB serum, penicillin–streptomycin (Life Technologies) and L-glutamin (Life Technologies))
and the serum lot was pretested for assay performance. On Day 1, 1–2 vials of PBMC were thawed in
a 37 ◦C water bath until only small ice crystals were visible. The cell suspension was transferred to ice
cold RPMI1640 (Life Technologies) and centrifuged at 1500 rpm for 5 min at 4 ◦C. The PBMC pellet
was re-suspended in T cell medium, containing 10 U/mL DNase1 and left to recover at RT for 1 h.
After 1 h, cells were counted with trypan blue and re-suspended in T cell medium at a concentration
of 107 cells/mL. Cells were plated at 20–100 µL per well in half-well 96 well plates (Greiner Bio-One,
Vilvoorde, Belgium) and cultured in the absence or presence of the indicated overlapping peptide
pools at 0.6 nmol/mL for 16–20 h at 37 ◦C/5% CO2. After the incubation period, the cells were used
for flow cytometric analysis.
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4.8. Flow Cytometry Staining and Analysis
Plates were centrifuged during 5 min at 1800 rpm and 4 ◦C. After aspiration of the supernatant,
cells were first washed with cold PBS (Life Technologies), centrifuged again and subsequently
incubated for 30 min with 150 µL per well of a fixable viability dye (Fixable Viability Dye eFluor
506, eBioscience, Vienna, Austria) diluted at 1 µL/mL in PBS for discrimination of live and
dead cells. After incubation, plates were centrifuged and cells were washed with PBS. Next,
Fc receptor blocking was performed by adding 25 µL per well of a 10% normal goat serum
(Sigma-Aldrich) solution in PBS/0.5% BSA. To identify antigen-specific T cells, the cells were stained
with the following antibodies: CD4-FITC (BD Pharmingen, Erembodegem, Belgium), CD137-PE
(BD Pharmingen), CD3-PerCp-Cy5.5 (BioLegend, London, UK), CD19-PE-CY7 (BioLegend) and
CD8-APC-H7 (BD Pharmingen). All antibodies were titrated to optimal dilution before use.
Acquisition was performed with a FACSCanto II flow cytometer using BD FACSDIVA software
v6.1.3 (BD Biosciences, San Jose, CA, USA) and (2.5–5) × 105 cells were acquired per sample.
Photo Multiplier Tube (PMT) voltages were set using CS & T beads and compensation was calculated
using single-stained samples. Data analysis was done using FACSDIVA v6.1.3 (BD Biosciences).
The following gating strategy was used: first, dead cells were gated out using the viability
dye and cells were gated on the lymphocyte population based on FSC/SSC properties. Within the
lymphocyte population, a gate was set around CD3+ CD19− cells and, subsequently, the CD4+ and
CD8+ population was gated in the CD3+ population with exclusion of double-positive T cells. Finally,
CD137 expression within the CD4+ or CD8+ population was evaluated. Background expression of
CD137 by the T cells was determined on T cells from cultures without peptides. Positive reactivity
to an antigen was predefined as a minimum 2-fold increase in CD137 positivity compared to the
unstimulated control. The gating of a representative sample is shown in Figure S1.
These studies were conducted in a laboratory that operates under exploratory research principles
using investigative protocols and assays.
4.9. Statistical Analyses
All statistical analyses were conducted using GraphPad Prism software. Tests were 2-sided and
values were considered significant at p ≤ 0.05.
5. Conclusions
Concerning the TAA expression at the mRNA level, we showed that MAGE-A3 and Sp17 were
overexpressed in only a minority of patients, BORIS was overexpressed in a moderate proportion of
tumors, while hTERT was overexpressed in most tumors and its expression was upregulated in FIGO
stages II, III, and IV EMCAR patients compared to FIGO stage I.
At the protein level, MUC1 was upregulated in primary, recurrent and metastatic EMCAR tumors
and in metastatic US tumors compared to normal tissues. For hTERT, the unexpected expression in
some normal tissues and our finding that expression was upregulated in normal endometrium led us
to question the usefulness of the antibody.
Vis-à-vis the endogenous T cell responses towards these antigens in patient blood samples,
we detected reactivity towards MAGE-A3, MUC1 and Sp17 in only a minority of patients,
while hTERT-specific endogenous T cell immunity could be detected in almost half of the
patients tested.
Altogether, these results point to MUC1 and hTERT as the most promising targets for application
in immunotherapeutic strategies for endometrial carcinoma and uterine sarcoma patients. However,
considering the value of neoantigens as immunotherapeutic targets, we propose to use whole
tumor-derived approaches for tumor vaccination in uterine cancer.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/17/9/1525/s1.
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